BioNTech Results Presentation Deck
Strong Clinical Execution in Oncology in 2021¹
Data Updates
Q4 2021
E
4 Randomized
Phase 2 Trial Starts
18
5 First-in-human
Phase 1 Trial Starts
SITC 2021
✓BNT111 Phase 1
✓BNT112 Phase 1/2
BNT211 Phase 1/2
✓ BNT111 -R/R Melanoma³
BNT113 - HPV16+ HNSCC
✓ BNT211 - CARVac
BNT221 - NEOSTIM
BNT151 - RiboCytokines
R/R, refractory/relapsed; HNSCC, head and neck squamous cell carcinoma;
NSCLC, non-small cell lung cancer; FPD, first patient dosed; 1 Includes updates through March 30,
2022; 2 BNT311 (Gen1046) and BNT312 (Gen1042) are partnered with Genmab; 3 Partnered with
Regeneron; 4 Autogene Cevumeran is partnered with Genentech
BNT3112 Phase 1/2
BNT3122 Phase 1/2
BNT411 Phase 1/2
ESMO-10 2021
BNT211 Phase 1/2
Milestone achieved
in full year 2021
Autogene Cevumeran4 (BNT122) -
Adjuvant colorectal cancer
BNT311-R/R NSCLC - FPD Dec 2021
✔BNT152+153 - RiboCytokines
BNT141 - RiboMabs - FPD Jan 2022
Milestone achieved in Q4 2021
and early 2022
BIONTECHView entire presentation